Publication | Closed Access

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

UrologyHistone Deacetylase InhibitorSingle-arm TrialMedicinePharmacologyPharmacotherapyAnti-cancer AgentProstatic DiseaseOncologyPhase Ii